SLC6A9, solute carrier family 6 member 9, 6536

N. diseases: 71; N. variants: 11
Disease: Schizophrenia ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.400 GeneticVariation disease BEFREE Association study of the excitatory amino acid transporter 2 (EAAT2) and glycine transporter 1 (GlyT1) gene polymorphism with schizophrenia in a Polish population. 31118638 2019
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.400 Biomarker disease BEFREE The glycine transporter 1 (GlyT1) has emerged as a key novel target for the treatment of schizophrenia. 30080045 2018
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.400 Biomarker disease BEFREE Numerous research groups have developed GlyT-1 inhibitors in the pursuit of providing a novel antipsychotic treatment for schizophrenia. 29338548 2018
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.400 Biomarker disease BEFREE The development of glycine transporter 1 (GlyT1) inhibitors may offer putative treatments for schizophrenia and other disorders associated with hypofunction of the glutaminergic N-methyl-d-aspartate (NMDA) receptor. 29969029 2018
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.400 GeneticVariation disease BEFREE PF-03463275 increased long-term potentiation only in SZs with peak effects at 40 mg twice a day (∼75% GlyT1 occupancy) and with a profile suggestive of an inverted U dose response.PF-03463275 was well-tolerated. 29499855 2018
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.400 Biomarker disease BEFREE We proposed simultaneously inhibiting DAAO and GlyT-1 may be more effective than inhibition of either in improving the cognitive and global functioning of schizophrenia patients. 26691576 2017
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.400 Biomarker disease BEFREE These results replicate previous reports of an inverted-U dose response curve and suggest further evaluation of GlyT1 inhibitors in schizophrenia negative symptoms is warranted. 27789188 2017
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.400 Biomarker disease BEFREE These findings are of translational value since GlyT1 inhibitors are already in clinical development to treat cognitive symptoms in schizophrenia. 26302655 2015
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.400 Biomarker disease PSYGENET Inhibition of glycine transporter 1 (GlyT1) augments N-methyl-D-aspartate receptor (NMDAR)-mediated transmission and represents a potential antipsychotic drug target according to the NMDAR hypofunction hypothesis of schizophrenia. 20647165 2011
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.400 Biomarker disease PSYGENET This may be relevant for the suggested clinical application of GlyT1 inhibitors in the treatment of cognitive deficits, including schizophrenia, which is characterized by cognitive inflexibility in addition to the positive symptoms of the disease. 19824767 2009
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.400 Biomarker disease PSYGENET We concluded that at least one susceptibility locus for schizophrenia may be located within or nearby SLC6A5, whereas SLC1A4, SLC1A5 and SLC6A9 are unlikely to be major susceptibility genes for schizophrenia in the Japanese population. 18638388 2008
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.400 Biomarker disease LHGDN We concluded that at least one susceptibility locus for schizophrenia may be located within or nearby SLC6A5, whereas SLC1A4, SLC1A5 and SLC6A9 are unlikely to be major susceptibility genes for schizophrenia in the Japanese population. 18638388 2008
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.400 Biomarker disease BEFREE We concluded that at least one susceptibility locus for schizophrenia may be located within or nearby SLC6A5, whereas SLC1A4, SLC1A5 and SLC6A9 are unlikely to be major susceptibility genes for schizophrenia in the Japanese population. 18638388 2008
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.400 Biomarker disease PSYGENET Unchanged GlyT1 suggests that glycine transport is not markedly affected in schizophrenia, and therefore that increased synaptic removal is not the basis for the putative deficit in glycine modulation of NMDA receptors in the disorder. 18400471 2008
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.400 Biomarker disease BEFREE Unchanged GlyT1 suggests that glycine transport is not markedly affected in schizophrenia, and therefore that increased synaptic removal is not the basis for the putative deficit in glycine modulation of NMDA receptors in the disorder. 18400471 2008
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.400 Biomarker disease BEFREE The new generation of GlyT1 inhibitors may represent a novel treatment of patients suffering from schizophrenia and/or other neuropathological conditions. 16611082 2006
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.400 GeneticVariation disease BEFREE Further studies with other GlyT1 variants, relating either to schizophrenia, psychotic symptoms or to therapeutic response in schizophrenia, are suggested. 16604304 2006